FB
FBLG.US FibroBiologics, Inc. Common Stock
- Market cap
- USD 6.57M
- P/E
- -
- P/B
- 1.45x
- ROE
- -302.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is FBLG.US undervalued?
Graham numberThe Graham number of FibroBiologics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
FibroBiologics, Inc. Common Stock fundamental analysis
No fundamental analysis for FibroBiologics, Inc. Common Stock yet.
FibroBiologics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatmen…
Full company profileFibroBiologics, Inc. Common Stock financial statements
FibroBiologics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -94.0K | -437K | -573K | -832K |
| Operating Income | -1.17M | -1.58M | -4.47M | -8.89M | -13.7M | -16.6M |
| EBITDA | - | -1.58M | -4.37M | -15.9M | -10.6M | -17.6M |
| Net Income | -1.17M | -1.58M | -5.12M | -16.5M | -11.2M | -18.6M |
| EPS | -0.72 | -0.97 | -3.15 | -10 | -6.79 | -8.35 |
| Balance Sheet | ||||||
| Total Assets | - | 468K | 4.82M | 11.8M | 16.4M | 9.62M |
| Total Liabilities | - | 1.76M | 8.82M | 10.6M | 13.7M | 3.46M |
| Shareholders' Equity | - | -1.29M | -4.00M | 1.25M | 2.74M | 6.16M |
| Cash & Short-term Investments | - | 407K | 2.27M | 9.16M | 14.0M | 4.89M |
| Total Debt | - | 1.30M | 7.52M | 1.75M | 10.6M | 2.41M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.17M | -1.41M | -4.07M | -6.40M | -11.9M | -16.4M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 495K | 184K | 262K |
| Free Cash Flow | -1.17M | -1.41M | -4.07M | -6.90M | -12.1M | -16.7M |
| Ratios | ||||||
| ROE | - | - | - | -1,315.6% | -408.1% | -302.9% |
| ROA | - | -338.0% | -106.2% | -139.5% | -67.9% | -193.8% |
| Debt to Equity | - | - | - | 1.39x | 3.86x | 0.39x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
FibroBiologics, Inc. Common Stock dividends
FibroBiologics, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Last stock split: 1:20 on Mar 30, 2026.
Who owns FibroBiologics, Inc. Common Stock
- Insiders 13.74%
- Institutions 14.40%
- Public & others 71.86%
- Shares outstanding 7.08M
- Free float 5.19M
Top funds holding FBLG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price M-A Glb Inc I USD | 280K | 3.95% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 24.2K | 0.34% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.57K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.27K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding FBLG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 30.3K | 0.43% | +2.33% | Jun 2026 |
| Vanguard Capital Management, LLC | 27.8K | 0.39% | -58.96% | Jun 2026 |
| Qube Research & Technologies | 24.3K | 0.34% | 0.00% | Jun 2026 |
| BlackRock Inc | 18.2K | 0.26% | -26.00% | Jun 2026 |
| Barclays PLC | 7.24K | 0.10% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 6.38K | 0.09% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 4.73K | 0.07% | +927.83% | Jun 2026 |
| Advisor Group Holdings, Inc. | 2.40K | 0.03% | +1,461.04% | Jun 2026 |
| Royal Bank of Canada | 1.52K | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 1.07K | 0.02% | -81.24% | Jun 2026 |
| Islay Capital Management, LLC | 169.00 | 0.00% | 0.00% | Jun 2026 |
| Coconut Grove Bank | 100.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 64.00 | 0.00% | -3.03% | Jun 2026 |
| Hanson Mcclain Inc | 13.00 | 0.00% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Fund Evaluation Group, LLC | 0.00 | 0.00% | -100.00% | Sep 2026 |
| Goss Wealth Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
FibroBiologics, Inc. Common Stock company profile
- Company name
- FibroBiologics, Inc. Common Stock
- Ticker
- FBLG.US
- Exchange
- USA Stocks
- Listed since
- Jan 31, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- June
- Address
- 455 East Medical Center Boulevard, Houston, TX, United States, 77598
- Phone
- 281 671 5150
- Website
- fibrobiologics.com
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FibroBiologics, Inc. Common Stock management
4- Mr. Peter O'HeeronFounder, Chairperson & CEO · born 1964
- Dr. Hamid Khoja Ph.D.Chief Scientific Officer · born 1970
- Mr. Ruben A. Garcia J.D.General Counsel · born 1977
- Mr. Jason D. Davis CPAChief Financial Officer · born 1972